Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 02, 2018

First-Line Ribociclib Plus Letrozole vs Placebo Plus Letrozole in HR+, HER2− Advanced Breast Cancer

Annals of Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Updated Results From MONALEESA-2, a Phase III Trial of First-Line Ribociclib Plus Letrozole Versus Placebo Plus Letrozole in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ann. Oncol 2018 Apr 27;[EPub Ahead of Print], GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, S Paluch-Shimon, M Campone, K Petrakova, K L Blackwell, EP Winer, W Janni, S Verma, P Conte, CL Arteaga, DA Cameron, S Mondal, F Su, M Miller, M Elmeliegy, C Germa, JO’Shaughnessy

Further Reading